EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH

View source ↗

Summary

EMA has authorized Qaialdo, a spironolactone product by Lipomed GmbH, for several conditions including edema, heart failure, liver cirrhosis with ascites, nephr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Edema
• Essential Hypertension
• Heart Failure
• Hyperaldosteronism
• Liver Cirrhosis with Ascites
• Nephrotic Syndrome

Drugs mentioned

• Qaialdo (spironolactone)

Snippet

Status: Authorised. Therapeutic area: Edema;Heart Failure;Liver Cirrhosis;Ascites;Nephrotic Syndrome;Hyperaldosteronism;Essential Hypertension. MAH: Lipomed GmbH. Decision date: 30/06/2026